FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer

Kathleen N. Moore, Ignace Vergote, Ana Oaknin, Nicoletta Colombo, Susana Banerjee, Amit Oza, Patricia Pautier, Karim Malek, Michael J. Birrer

Research output: Contribution to journalReview article

Abstract

Mirvetuximab soravtansine, an antibody-drug conjugate that binds with high affinity to folate receptor-α to provide tumor-directed delivery of the potent microtubule-disrupting agent DM4, has emerged as a promising investigational agent for the treatment of ovarian cancer, particularly in the setting of platinum-resistant disease. Here we describe the rationale and design of FORWARD I (NCT02631876), the first randomized, multicenter Phase III study to compare the safety and efficacy of mirvetuximab soravtansine versus investigator's choice of chemotherapy in women with folate receptor-α-positive, platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer. Patients will be randomized in a 2:1 ratio. The primary end point is progression-free survival, and key secondary objectives include comparison of overall response rates, overall survival and duration of response.

Original languageEnglish
Pages (from-to)1669-1678
Number of pages10
JournalFuture Oncology
Volume14
Issue number17
DOIs
Publication statusPublished - Jul 1 2018

Keywords

  • antibody-drug conjugate
  • folate receptor-α
  • mirvetuximab soravtansine
  • ovarian cancer
  • Phase III trial
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Moore, K. N., Vergote, I., Oaknin, A., Colombo, N., Banerjee, S., Oza, A., Pautier, P., Malek, K., & Birrer, M. J. (2018). FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncology, 14(17), 1669-1678. https://doi.org/10.2217/fon-2017-0646